COR Mar pH Pharma Co., Ltd. split into two: pH Pharma and Peak Bio
303 Jan Awarded US-DoD grant for COVID-19 Treatment
201 May PHP-201 Phase III IND approval by MFDS
303 Jan IND approved for Ph. II AATD study (GB, IE)
ADC Dec Signed an ADC co-development contract with Venn DC
ADC Oct Signed an ADC co-development contract with Immunome
303 Jul Completed Phase Ib MAD study in (US)
303 Jul Awarded Foundation grant for PHP-303 Alpha-1 research
COR May Asia Research Center opened in Pangyo (KR)
201 Mar PHP-201 Phase IIb results presented at APAO
303 Jan PHP-303 Phase Ib (MAD) initiated (US)
303 Dec PHP-303 Phase Ib (SAD) initiated (US)
201 Dec Completed Phase IIb clinical study report (CSR)
ADC Sep Patented an additional in-house novel toxin
303 Aug PHP-303 Phase Ib initiated (US)
201 Jun Completed Phase IIb study (KR)
COR Apr Global Research Center opened in Silicon Valley (US)
COR Mar Signed an investment contract with Pliant Therapeutics
ADC Feb Two toxins in-licensed from Purdue University
ADC Oct Patented our first in-house novel toxin
201 Feb PHP-201 Phase IIb study initiated (KR)
303 Feb PHP-303 acquired from Bayer
ADC Nov Initiated ADC toxin research program (Torpedo)
201 Oct IND is approved for Phase IIb study (KR)
COR Feb pH Pharma Inc. is established in Silicon Valley (US)
201 Feb PHP-201 in-licensed from Amakem Therapeutics
COR Sep pH Pharma Co., Ltd. established
EN 
KR